Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS by Ganggang Wang, Lin Su, Yanjun Liu, Xiaohan Yang, Yi Li, Qi Mei, Qi Mei, Wen Gao

“…BackgroundThe advent of tisagenlecleucel has been a major advance in the pharmacological treatment of relapsed/refractory B-cell acute lymphoblastic leukemia in children and adolescents. However, further research is required to better define its safety profile.ObjectivesTo determine the cardiovascular toxicity of tisagenlecleucel in children and adolescents.MethodsThe US Food and Drug Administration’s Adverse Event Reporting System was searched to identify cardiovascular adverse events (CVAEs) related to tisagenlecleucel in pediatric patients up to the age of 18 years.ResultsThe median time to onset of tisagenlecleucel-associated CVAEs was shorter than that of tisagenlecleucel-associated non-CVAEs (3 days [interquartile range (IQR) 1, 6] vs. 7 days [IQR 2, 54]). …”
Get full text

FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers by Yongchang Tang, Hong Wang, Jiankun Zhang, Chunhui Yang, Fei Xu, Yan Song, Tianen Li, Qiangbo Zhang

“…FMS-like tyrosine kinase 3 (FLT3) is a frequently mutated gene in acute myeloid leukemia (AML). However, its role in solid cancers remains poorly understood. …”
Get full text

Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine by Kazuya Sato, Nodoka Tsukada, Junki Inamura, Shigetsuna Komatsu, Keisuke Sato, Masayo Yamamoto, Motohiro Shindo, Kentaro Moriichi, Yusuke Mizukami, Mikihiro Fujiya, Yoshihiro Torimoto, Toshikatsu Okumura

“…Myeloid sarcoma (MS), which involves extramedullary lesions, is classified as a unique subtype of acute myeloid leukemia (AML). At present, no standard treatments for MS have been established. …”
Get full text

Autonomous Defense Based on Biogenic Nanoparticle Formation in Daunomycin-Producing <i>Streptomyces</i> by Karel Beneš, Vladislav Čurn, Baveesh Pudhuvai, Jaroslav Motis, Zuzana Michalcová, Andrea Bohatá, Jana Lencová, Jan Bárta, Michael Rost, Andreas Vilcinskas, Vladimír Maťha

“…Daunomycin is a chemotherapeutic agent widely used for the treatment of leukemia, but its toxicity toward healthy dividing cells limits its clinical use and its production by fermentation. …”
Get full text

Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-Thymoglobulin by Itai Falicovich, Boaz Nachmias, Shlomo Elias, Eran Zimran, Adir Shaulov, Polina Stepensky, Batia Avni, Sigal Grisariu

“…Additionally, the ATG-F group had more myeloid leukemia and myelodysplastic syndrome patients, while the ATG-T group had more lymphoma patients.ResultsThe cumulative incidence of acute GVHD (aGVHD) grade II-IV and chronic GVHD (cGVHD) showed no significant differences. …”
Get full text

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies by Yan-Ruide Li, Ying Fang, Siyue Niu, Yichen Zhu, Yuning Chen, Zibai Lyu, Enbo Zhu, Yanxin Tian, Jie Huang, Valerie Rezek, Scott Kitchen, Tzung Hsiai, Jin J. Zhou, Pin Wang, Wanxing Chai-Ho, Sunmin Park, Christopher S. Seet, Caspian Oliai, Lili Yang

“…In preclinical mouse models, CAR-NKT cells exhibit strong BM homing and effectively target BM-resident malignant blast cells, including CD33-low/negative leukemia stem and progenitor cells. Furthermore, CAR-NKT cells synergize with hypomethylating agents, enhancing tumor-killing efficacy. …”
Get full text

Treatment of uterine fibroid: focus on endometrial receptivity. A pilot randomized prospective study by Yulia E. Dobrokhotova, Irina A. Lapina, Valeriia M. Gomzikova, Yury А. Sorokin, Eleonora T. Khatagova, Ayshan R. Allakhverdieva, Mariya A. Olkhovskaya

“…After 3 months of therapy, a more prominent improvement in the endometrium receptor status was noted in the mifepristone group due to a decrease in the ratio of progesterone to estrogen [2.21±0.47 vs 3.34 (1.42; 5.83) in group 1 and 2.35±0.35 vs 3.78 (3.11; 5.05) in group 2] and normalization of the level of leukemia inhibitory factor (mean value 9.4±3.51 vs 6.95±1.76). …”
Get full text

Cdk6’s functions are critically regulated by its unique C-terminus by Alessia Schirripa, Helge Schöppe, Sofie Nebenfuehr, Markus Zojer, Thorsten Klampfl, Valentina Kugler, Belinda S. Maw, Huriye Ceylan, Iris Z. Uras, Lisa Scheiblecker, Elisabeth Gamper, Ulrich Stelzl, Eduard Stefan, Teresa Kaserer, Veronika Sexl, Karoline Kollmann

“…We analyzed the impact of CDK6’s C-terminus on its functions in a leukemia model, revealing a central role in promoting proliferation. …”
Get full text

The characteristics of chronic benzene poisoning in 176 Chinese occupational population cases by Lian Gou, Lian Gou, Xingyu Ma, Lili Huang, Lili Huang, Mei Qiu, Ruiqing Guo, Jun Jia, Peiyu Xu, Nan Lian

“…Benzene is a widespread environmental carcinogen known to induce leukemia. Chronic benzene poisoning is a significant occupational health issue in China, particularly among workers exposed to benzene. …”
Get full text

Inhibition of NLRP3 enhances pro-apoptotic effects of FLT3 inhibition in AML by Helene Sieberer, Michela Luciano, Diana Amend, Constantin Blöchl, Anna Eglseer, Alina Steinkellner, Sebastian Rieser, Ancuela Andosch, Philip Steiner, Laura Hummer, Peter W. Krenn, Hieu-Hoa Dang, Christian G. Huber, Fritz Aberger, Theresa Neuper, Jutta Horejs-Hoeck

“…Abstract FLT3 mutations occur in approximately 25% of all acute myeloid leukemia (AML) patients. While several FLT3 inhibitors have received FDA approval, their use is currently limited to combination therapies with chemotherapy, as resistance occurs, and efficacy decreases when the inhibitors are used alone. …”
Get full text

A Green Approach to the Production of Hybrid Diindolylmethane-Phenylboronic Acids via a 3MCR: Promising Antineoplasic Molecules by Mónica Zarco Juarez, Joel Omar Martínez, Olivia Noguez Cordova, María Inés Nicolás Vazquez, Teresa Ramírez-Apan, Javier Pérez Flores, René Miranda Ruvalcaba, Gabriel Arturo Arroyo Razo

“…Moreover, the activity of these target molecules was evaluated in the presence of six cancer cell lines (U251 = glia of the central nerve system, PC-3 = prostate, K562 = leukemia, HCT-15 = colon, MCF-7 = breast, and SKLU-1 = lung), which resulted in the meta-regioisomer being the most active. …”
Get full text

Muscle contractile properties and perceived fatigue in the general and diseased population by Isa H. Mast, Neeltje A. E. Allard, Dominique tenHaaf, Anouk A. F. Stoffels, Lando Janssen, Hieronymus W. H. vanHees, Silvie Timmers, Bregina T. P. Hijmans‐Kersten, Maria T. E. Hopman, Laurien M. Buffart

“…We pooled data on perceived fatigue, physical fitness, and contractile properties from six studies, including a control group (n = 90), cancer survivors (n = 27), patients with chronic obstructive pulmonary disease (COPD; n = 16), chronic myeloid leukemia (CML; n = 20), and statin users (n = 64). …”
Get full text

Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL by Willem P. J. Cox, Noël M. M. Dautzenberg, Linde Dekker, Tesa Klenovsek, Annelisa M. Cornel, Marliek van Hoesel, Dorette S. van Ingen Schenau, Reno S. Bladergroen, Roland P. Kuiper, Laurens T. van der Meer, Friso G. Calkoen, Stefan Nierkens, Frank N. van Leeuwen

“…Abstract: Loss of p53 function predicts a dismal outcome in relapsed B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Chimeric antigen receptor T-cell (CAR T) therapy was recently approved to salvage relapsed/refractory BCP-ALL. …”
Get full text

Clofarabine induces tumor cell apoptosis, GSDME-related pyroptosis, and CD8+ T-cell antitumor activity via the non-canonical P53/STING pathway by Jing Chen, Jie Wu, Xiang Chen, Qian Tao, Nian Liu, Cong Peng, Can Lu, Qiuqiu Li

“…Background Clofarabine (Clo) is a Food and Drug Administration (FDA)-approved drug for the treatment of acute lymphoblastic leukemia; however, its effects on solid tumors remain largely unknown.Methods In vitro and in vivo experiments have demonstrated the cytotoxic effects of Clo on melanoma and lung cancer. …”
Get full text

Changing trends from inguinal radical orchiectomy to testis-sparing surgery in pediatric testicular tumors by Özlem Balcı, Aslı Nur Abay, Şule Yeşil, İbrahim Karaman, İsmet Faruk Özgüner, Burçak Kurucu, Derya Erdoğan, Gürses Şahin, Ayşe Karaman

“…Testicular biopsy was performed in 9 cases for testicular involvement of Leukemia and Lymphoma. No recurrence was detected with a median follow-up of 6.5 years. …”
Get full text

Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment by Cristina Camps-Fajol, Debora Cavero, Jordi Minguillón, Jordi Surrallés

“…Focusing on anticancer drugs, in the last years several PPI modulators have entered clinical trials and venetoclax, which targets Bcl-2 family proteins, has been approved for treating different types of leukemia. This review discusses the clinical development status of drugs modulating several PPIs, such as MDM2–4/p53, Hsp90/Hsp90, Hsp90/CDC37, c-Myc/Max, KRAS/SOS1, CCR5/CCL5, CCR2/CCL2 or Smac/XIAP, in cancer drug discovery.…”
Get full text

Exploring the Anti-PANoptosis Mechanism of Dachaihu Decoction Against Sepsis-Induced Acute Lung Injury: Network Pharmacology, Bioinformatics, and Experimental Validation by Yang Z, Kao X, Zhang L, Huang N, Chen J, He M

“…Enrichment analysis showed that DCHD against SALI via anti-PANoptosis by modulating tumor necrosis factor (TNF), AGE-RAGE, phosphoinositide 3-kinase (PI3K)-AKT, and Toll-like receptor signaling pathways by targeting Casp3, cellular tumor antigen p53 (TP53), B-cell lymphoma 2 (Bcl2), toll-like receptor-4 (TLR4), STAT3, STAT1, RELA, NF-κB1, myeloid cell leukemia-1 (MCL1), JUN, IL-1β, HSP90AA1, Casp9, Casp8, and Bcl2l1. …”
Get full text

Changes in the Expression of Mitochondrial Morphology-Related Genes during the Differentiation of Murine Embryonic Stem Cells by Jeong Eon Lee, Bong Jong Seo, Min Ji Han, Yean Ju Hong, Kwonho Hong, Hyuk Song, Jeong Woong Lee, Jeong Tae Do

“…Pluripotent ESCs maintain stemness in the presence of leukemia inhibitory factor (LIF) via the JAK-STAT3 pathway but lose pluripotency and differentiate in response to the withdrawal of LIF. …”
Get full text

GC1126A, a novel ADAMTS13 mutein, evades autoantibodies in immune-mediated thrombotic thrombocytopenic purpura by Heechun Kwak, Gahee Choi, Suyong Kim, Ji-Min Park, Youngeun Kwon, Yongmin Lee, Chaemok Lee, Shangbin Yang, Spero Cataland, Sunghyun Kim, Soo-Mee Bang, Jae-Ho Yoon, Wooin Lee, Hyun-Ja Nam

Get full text

Assessment of Physicochemical Properties of Rituximab Related to Its Immunomodulatory Activity by Mariana P. Miranda-Hernández, Carlos A. López-Morales, Nancy D. Ramírez-Ibáñez, Nelly Piña-Lara, Nestor O. Pérez, Aarón Molina-Pérez, Jorge Revilla-Beltri, Luis F. Flores-Ortiz, Emilio Medina-Rivero

“…Rituximab is a chimeric monoclonal antibody employed for the treatment of CD20-positive B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. …”
Get full text